Gina Wentling   Posted in News, Presentations    Aug 16th, 2017

Utilizing devTOXqP in a Combined Testing Approach for Identifying Developmental Toxicity Liability of Chemicals [Webinar Slides]

Why develop devTOX? Reduce prevalence of birth defects and decrease animal testing. Our approach represents a unique opportunity to screen compound safety using a human endpoint. devTOX quickPredict is a predictive, targeted biomarker assay. (devTOX Discovery, on the other hand, is a predictive, untargeted metabolomics assay.) Jessica Palmer presented this webinar in October 2016. If you would like to have her go over these slides with you, email gwentling@stemina.com to set up an appointment.

Utilizing devTOXqP in a Combined Testing Approach for Identifying Developmental Toxicity Liability of Chemicals